Overview

Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Status:
Completed
Trial end date:
2017-05-23
Target enrollment:
Participant gender:
Summary
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study M12-671 (NCT01931670).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie